Congenital cystic kidney disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:43 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Congenital cystic kidney disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the safety and tolerability of azathioprine in patients with autosomal dominant polycystic kidney and liver disease https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-tolerability-of-azathioprine-in-patients-with-autosomal-dominant-polycystic-kidney-and-liver-disease/ Wed, 29 Apr 2026 15:10:04 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-tolerability-of-azathioprine-in-patients-with-autosomal-dominant-polycystic-kidney-and-liver-disease/ This study focuses on individuals living with Autosomal Dominant Polycystic Kidney Disease, a condition where fluid-filled sacs, or cysts, grow in the kidneys and sometimes the liver. The purpose of the study is to evaluate the safety and how well the body tolerates the medication azathioprine. This medication is taken as an oral tablet, meaning it is swallowed by mouth.

Participants in the study will take different doses of the medication over a period of time. During the study, health aspects such as liver function, which refers to how well the liver is working, and leucopenia, which is a low level of white blood cells in the blood, will be monitored. The study also looks at how the treatment might affect the size of the kidneys and the liver, as well as the eGFR, a measure used to check how well the kidneys are filtering waste from the blood.

]]> A study to evaluate the effectiveness and safety of ursodeoxycholic acid in patients with hepatorenal polycystic diseases. https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-ursodeoxycholic-acid-in-patients-with-hepatorenal-polycystic-diseases/ Wed, 29 Apr 2026 15:09:13 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-ursodeoxycholic-acid-in-patients-with-hepatorenal-polycystic-diseases/ This study focuses on Hepatorenal polycystic diseases, which are conditions where fluid-filled sacs, known as cysts, grow in both the liver and the kidneys. The goal of the research is to evaluate the effectiveness and safety of ursodeoxycholic acid compared to a placebo in slowing the growth of these cysts in the liver.

During the study, participants will be monitored to see how the medication affects the size of the liver and kidney cysts, as well as overall organ function. This includes checking renal function, which refers to how well the kidneys filter waste from the blood, and monitoring liver profile markers through blood tests to ensure safety. Researchers will also look at genetic information and certain proteins or molecules in the blood, often called biomarkers, to better understand how the disease progresses and how individuals respond to the treatment.

]]> Testing dapagliflozin to slow kidney function decline in patients with autosomal dominant polycystic kidney disease https://clinicaltrials.eu/trial/testing-dapagliflozin-to-slow-kidney-function-decline-in-patients-with-autosomal-dominant-polycystic-kidney-disease/ Wed, 29 Apr 2026 15:07:49 +0000 https://clinicaltrials.eu/trial/testing-dapagliflozin-to-slow-kidney-function-decline-in-patients-with-autosomal-dominant-polycystic-kidney-disease/ This study is looking at autosomal dominant polycystic kidney disease, which is an inherited condition where multiple fluid-filled sacs called cysts develop in the kidneys over time. These cysts can cause the kidneys to grow larger and gradually lose their ability to work properly. The study will use a medication called dapagliflozin, which is a medicine that helps the kidneys remove extra sugar from the body through urine. Some participants will receive dapagliflozin while others will receive placebo. The purpose of the study is to find out whether dapagliflozin can slow down the decline in kidney function in people with this disease.

Participants in this study will take the study medication for about three years. During this time, they will have regular visits where blood tests will be done to measure how well their kidneys are working. These measurements will help researchers understand if the medication is helping to slow down the loss of kidney function. Some participants will also have imaging scans to measure the size of their kidneys after one year of treatment. The study is designed for adults between 18 and 60 years of age who have signs that their kidney disease is getting worse more quickly than usual.

Throughout the study, doctors will monitor participants for any unwanted effects of the medication and will check how the kidneys are responding to treatment. After completing the treatment period, participants will have follow-up visits where additional measurements will be taken to see what happens after stopping the medication. The study will collect information about serious health problems and specific side effects that may be related to the treatment. All of this information will help researchers understand whether this medication could be a useful treatment option for people living with polycystic kidney disease.

]]> Study of ABBV-CLS-628 to evaluate safety and effectiveness in adults with Autosomal Dominant Polycystic Kidney Disease https://clinicaltrials.eu/trial/study-of-abbv-cls-628-to-evaluate-safety-and-effectiveness-in-adults-with-autosomal-dominant-polycystic-kidney-disease/ Wed, 29 Apr 2026 15:06:28 +0000 https://clinicaltrials.eu/trial/study-of-abbv-cls-628-to-evaluate-safety-and-effectiveness-in-adults-with-autosomal-dominant-polycystic-kidney-disease/ This study focuses on Autosomal Dominant Polycystic Kidney Disease (ADPKD), a genetic condition where fluid-filled cysts develop in the kidneys, causing them to enlarge and potentially lose function over time. The study aims to evaluate a new medication called ABBV-CLS-628, which is given through intravenous administration, along with a placebo to determine if the treatment is safe and effective for adults with this condition.

The study medication ABBV-CLS-628 is a type of monoclonal antibody, which is a protein designed to work with the body’s immune system. During the study, participants will receive either the study medication or a placebo through an injection into a vein. The treatment period will last approximately 96 weeks, during which the size of the kidneys and their function will be monitored.

Throughout the study, various measurements will be taken to track changes in kidney size using MRI scans and to monitor kidney function. The study will involve regular visits to evaluate how well the treatment is working and to check for any potential side effects. Participants will be randomly assigned to either receive the actual medication or the placebo, and neither the participants nor the study doctors will know which treatment is being given.

]]> Study on Chronic Kidney Disease and Polycystic Kidney Disease Using Pyruvic Acid and MRI for Patients with These Conditions https://clinicaltrials.eu/trial/study-on-chronic-kidney-disease-and-polycystic-kidney-disease-using-pyruvic-acid-and-mri-for-patients-with-these-conditions/ Wed, 29 Apr 2026 15:05:22 +0000 https://clinicaltrials.eu/trial/study-on-chronic-kidney-disease-and-polycystic-kidney-disease-using-pyruvic-acid-and-mri-for-patients-with-these-conditions/ This clinical trial focuses on studying chronic kidney disease and autosomal dominant polycystic kidney disease, which are conditions affecting the kidneys. The study uses a special type of imaging called MRI (magnetic resonance imaging) to look at changes in the kidneys’ metabolism. The treatment involves an injection of a substance called Hyperpolarized [1-13C]pyruvate, which helps make the MRI images clearer and more detailed.

The purpose of the study is to understand how these kidney diseases change the way the kidneys process energy. By using the MRI with the special pyruvate injection, researchers hope to see differences in how the kidneys of healthy people and those with kidney disease work. This includes looking at how the kidneys produce certain substances like lactate and alanine, which are related to energy use in the body. The study will include healthy volunteers as well as patients with chronic kidney disease and polycystic kidney disease.

Participants in the study will receive the pyruvate injection and then undergo an MRI scan. This will help researchers see the metabolic changes in the kidneys. The study aims to find out if these changes are linked to other signs of kidney damage, such as fibrosis (scarring) and inflammation, which are often seen in kidney disease. The information gathered from this study could help improve understanding of these diseases and lead to better ways to diagnose and treat them in the future.

]]> Study Comparing Metformin and Tolvaptan for Adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD) https://clinicaltrials.eu/trial/study-comparing-metformin-and-tolvaptan-for-adults-with-autosomal-dominant-polycystic-kidney-disease-adpkd/ Wed, 29 Apr 2026 15:03:11 +0000 https://clinicaltrials.eu/trial/study-comparing-metformin-and-tolvaptan-for-adults-with-autosomal-dominant-polycystic-kidney-disease-adpkd/ This clinical trial is focused on studying a condition called Autosomal Dominant Polycystic Kidney Disease (ADPKD). This is a genetic disorder that causes numerous cysts to grow in the kidneys, which can lead to kidney failure over time. The study is comparing two treatments: Metformin and Tolvaptan. Metformin is commonly used to treat diabetes, but researchers are exploring its potential benefits for ADPKD. Tolvaptan is a medication specifically used to slow down the progression of kidney disease in ADPKD patients.

The purpose of the study is to determine if taking 1500 mg of Metformin daily for two years is as effective or not inferior to Tolvaptan in slowing down the decline of kidney function in people with ADPKD. Participants in the study will be randomly assigned to receive either Metformin or Tolvaptan. The study will last for two years, during which participants will have regular check-ups to monitor their kidney function and overall health.

Throughout the study, the main focus will be on measuring the change in kidney function, specifically looking at the estimated glomerular filtration rate (eGFR), which is a test used to check how well the kidneys are working. Additionally, the study will assess changes in the size of the kidneys using a CT-scan at 12 and 24 months. This research aims to provide valuable insights into the effectiveness of Metformin compared to Tolvaptan in managing ADPKD.

]]> Study on the Safety of Rotigotine for Patients with Autosomal Dominant Polycystic Kidney Disease https://clinicaltrials.eu/trial/study-on-the-safety-of-rotigotine-for-patients-with-autosomal-dominant-polycystic-kidney-disease/ Wed, 29 Apr 2026 15:02:59 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-rotigotine-for-patients-with-autosomal-dominant-polycystic-kidney-disease/ This clinical trial is focused on studying the safety of a medication called rotigotine in patients with a condition known as autosomal dominant polycystic kidney disease (ADPKD). ADPKD is a genetic disorder that causes numerous cysts to form in the kidneys, potentially leading to kidney failure. The treatment being tested is a transdermal patch called Neupro, which delivers rotigotine through the skin. The study will use two different strengths of the patch: 2 mg/24 hours and 4 mg/24 hours.

The main purpose of the study is to evaluate the safety of using the 4 mg/24 hours patch over a period of 24 months. Participants will be monitored for any adverse reactions, including serious ones, that may occur during this time. The study will also look at changes in kidney size using MRI scans, kidney function, blood pressure, quality of life, and other markers related to ADPKD progression. Additionally, the study will assess how well participants adhere to the treatment and their willingness to continue it long-term.

Throughout the study, participants will undergo regular check-ups and tests to monitor their health and the effects of the treatment. The study aims to provide valuable information on the safety and potential benefits of rotigotine for individuals with ADPKD, contributing to better management of this condition in the future.

]]> Study of Empagliflozin for Patients with Autosomal Dominant Polycystic Kidney Disease https://clinicaltrials.eu/trial/study-of-empagliflozin-for-patients-with-autosomal-dominant-polycystic-kidney-disease/ Wed, 29 Apr 2026 14:48:00 +0000 https://clinicaltrials.eu/trial/study-of-empagliflozin-for-patients-with-autosomal-dominant-polycystic-kidney-disease/ This clinical trial is focused on studying a condition called Autosomal Dominant Polycystic Kidney Disease (ADPKD). This is a genetic disorder that causes numerous cysts to grow in the kidneys, which can lead to kidney damage over time. The trial will explore the use of a medication called Empagliflozin, which is taken as a 10 mg film-coated tablet. The purpose of the study is to investigate the safety of Empagliflozin in managing kidney growth in patients with ADPKD.

Participants in the study will be randomly assigned to receive either Empagliflozin or a placebo. The study will last for a period of 18 months, during which participants will have regular check-ups to monitor their kidney health and overall well-being. The main focus will be on observing any changes in the size of the kidneys over the course of the treatment.

Throughout the study, participants will be required to attend scheduled visits and undergo various tests to ensure their safety and to gather important data about the effects of the treatment. The study aims to provide valuable insights into the potential benefits of Empagliflozin for individuals living with ADPKD.

]]> Study on the Safety and Effects of Tolvaptan for Infants and Young Children with Autosomal Recessive Polycystic Kidney Disease https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-tolvaptan-for-infants-and-young-children-with-autosomal-recessive-polycystic-kidney-disease/ Wed, 29 Apr 2026 14:29:51 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-tolvaptan-for-infants-and-young-children-with-autosomal-recessive-polycystic-kidney-disease/ This clinical trial is focused on studying a condition known as Autosomal Recessive Polycystic Kidney Disease (ARPKD), which affects the kidneys of infants and young children. The trial will explore the effects of a medication called Tolvaptan, also known by its code name OPC-41061. Tolvaptan is an oral suspension, meaning it is a liquid medicine taken by mouth. It is designed to help manage the symptoms of ARPKD by potentially reducing the need for certain medical treatments that support kidney function.

The purpose of this study is to evaluate how well Tolvaptan works in infants and children aged 28 days to less than 12 weeks who have been diagnosed with ARPKD. The trial will observe the safety, tolerability, and effectiveness of Tolvaptan over a period of time. Participants will receive the medication and be monitored for any changes in their condition, including the size of their kidneys and overall growth. The study will also look at how the medication is tolerated by the young participants and any side effects that may occur.

Throughout the study, various assessments will be conducted to track the progress of the participants. These assessments will include regular check-ups to measure kidney function, growth, and other health indicators. The trial aims to provide valuable information on how Tolvaptan can be used to help manage ARPKD in young children, potentially improving their quality of life and reducing the need for more intensive treatments. The study is expected to continue until 2027, allowing for comprehensive data collection and analysis.

]]> Study on the Safety and Effects of Tolvaptan for Children with Autosomal Recessive Polycystic Kidney Disease (ARPKD) https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-tolvaptan-for-children-with-autosomal-recessive-polycystic-kidney-disease-arpkd/ Wed, 29 Apr 2026 14:29:42 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-tolvaptan-for-children-with-autosomal-recessive-polycystic-kidney-disease-arpkd/ This clinical trial is focused on studying a condition known as Autosomal Recessive Polycystic Kidney Disease (ARPKD), which affects the kidneys in infants and children. The trial will use a medication called Tolvaptan, which is available in different forms such as oral suspension and tablets. The tablets are marketed under names like Jinarc and Samsca. The purpose of the study is to evaluate the safety of Tolvaptan in young patients with ARPKD.

Participants in the study will receive Tolvaptan over a period of up to 18 months. The study will monitor the safety and tolerability of the medication, which means checking for any side effects or reactions. The trial will also look at how the medication affects the growth and development of the children, including changes in kidney size and function. The study will involve regular check-ups and assessments to ensure the well-being of the participants.

Throughout the trial, researchers will gather information on how well Tolvaptan works in managing ARPKD in children. This includes observing any changes in kidney function and overall health. The study aims to provide valuable insights into the treatment of ARPKD, potentially improving the quality of life for those affected by this condition. Participants will be closely monitored by healthcare professionals to ensure their safety and to gather accurate data on the effects of the medication.

]]> Study on the Effects of Amiloride and Sodium Chloride on Vascular Stiffness in Patients with Polycystic Kidney Disease https://clinicaltrials.eu/trial/study-on-the-effects-of-amiloride-and-sodium-chloride-on-vascular-stiffness-in-patients-with-polycystic-kidney-disease/ Wed, 29 Apr 2026 14:29:04 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-amiloride-and-sodium-chloride-on-vascular-stiffness-in-patients-with-polycystic-kidney-disease/ This clinical trial is focused on studying Autosomal Dominant Polycystic Kidney Disease (ADPKD), a genetic condition that affects the kidneys and can lead to the development of numerous cysts. The study aims to explore whether a high-salt diet worsens arterial stiffness in patients with ADPKD and if treatment with amiloride, a medication that helps the body get rid of excess salt and water, can prevent these effects. The trial will also investigate if amiloride can further reduce arterial stiffness when patients follow a low-salt diet.

Participants in the study will be divided into groups to receive different treatments. Some will receive a salt supplement, while others will receive a placebo, which is a substance with no active medication. The study will also involve the use of sodium chloride and potato starch as part of the treatment regimen. The trial will last for a period of up to four weeks, during which participants will take the treatments orally, in the form of tablets or capsules.

The main goal of the study is to observe changes in arterial stiffness, which is a measure of how flexible or stiff the arteries are, in response to the treatments. Additional observations will include blood pressure measurements over 24 hours, and blood tests to check for signs of inflammation and other related markers. Some participants may also undergo MRI scans to measure sodium levels in the body. This research will help to understand the impact of salt intake and amiloride treatment on arterial health in individuals with ADPKD.

]]> Study on Hydrochlorothiazide and Tolvaptan for Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) https://clinicaltrials.eu/trial/study-on-hydrochlorothiazide-and-tolvaptan-for-patients-with-autosomal-dominant-polycystic-kidney-disease-adpkd/ Wed, 29 Apr 2026 14:24:12 +0000 https://clinicaltrials.eu/trial/study-on-hydrochlorothiazide-and-tolvaptan-for-patients-with-autosomal-dominant-polycystic-kidney-disease-adpkd/ This clinical trial is focused on studying Autosomal Dominant Polycystic Kidney Disease (ADPKD), a condition that causes the formation of cysts in the kidneys, leading to a gradual loss of kidney function. The study will explore the effects of adding hydrochlorothiazide, a medication commonly used to treat high blood pressure, to the current treatment with tolvaptan, a drug that helps protect the kidneys in ADPKD patients. Tolvaptan is known to have side effects that increase urine production, which can be uncomfortable for patients. The aim is to see if hydrochlorothiazide can improve the effectiveness of tolvaptan and reduce these side effects.

The purpose of the study is to investigate whether the combination of hydrochlorothiazide and tolvaptan can slow down the decline in kidney function and improve the quality of life for patients with ADPKD. Participants in the study will be randomly assigned to receive either hydrochlorothiazide or a placebo, in addition to their regular tolvaptan treatment. The study will last for a period of time, during which participants will have regular check-ups to monitor their kidney function and overall health.

Throughout the study, researchers will collect data on various health indicators, such as changes in kidney function, urine volume, and blood pressure. They will also assess the participants’ quality of life through questionnaires. The results of this study could provide valuable insights into improving treatment options for individuals living with ADPKD.

]]> Ogólnopolskie Stowarzyszenie Moje Nerki https://clinicaltrials.eu/organisation/ogolnopolskie-stowarzyszenie-moje-nerki/ Wed, 29 Apr 2026 13:34:19 +0000 https://clinicaltrials.eu/organisation/ogolnopolskie-stowarzyszenie-moje-nerki/ The National Association “My Kidneys” (OSMN) is a nationwide public benefit organization. It brings together patients with chronic kidney disease (CKD), dialysis patients, those in the pre-dialysis stage, kidney transplant recipients, as well as their families and caregivers from all over the country. The association’s mission is primarily education and the promotion of prevention and the idea of transplantation, organizing free tests and lectures on the occasion of World Kidney Day, raising awareness of CKD, and providing support for patients.

]]>